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Objective. SH3 domain–binding protein 2
(SH3BP2) is a signaling adapter protein that regulates
the immune and skeletal systems. The present study was
undertaken to investigate the role of SH3BP2 in arthri-
tis using 2 experimental mouse models, i.e., human
tumor necrosis factor –transgenic (hTNF-Tg) mice
and mice with collagen-induced arthritis (CIA).
Methods. First, Sh3bp2/ and wild-type
(Sh3bp2/) mice were crossed with hTNF-Tg mice.
Inflammation and bone loss were examined by clinical
inspection and histologic and microcomputed tomo-
graphy analysis, and osteoclastogenesis was evaluated
using primary bone marrow–derived macrophage
colony-stimulating factor–dependent macrophages
(BMMs). Second, CIA was induced in Sh3bp2/ and
Sh3bp2/ mice, and the incidence and severity of
arthritis were evaluated. Anti–mouse type II collagen
(CII) antibody levels were measured by enzyme-linked
immunosorbent assay, and lymph node cell responses to
CII were determined.
Results. SH3BP2 deficiency did not alter the
severity of joint swelling but did suppress bone erosion
in the hTNF-Tg mouse model. Bone loss at the talus and
tibia was prevented in Sh3bp2//hTNF-Tg mice com-
pared to Sh3bp2//hTNF-Tg mice. RANKL- and
TNF-induced osteoclastogenesis was suppressed in
Sh3bp2/ mouse BMM cultures. NF-ATc1 nuclear
localization in response to TNF was decreased in
Sh3bp2/ mouse BMMs compared to Sh3bp2/
mouse BMMs. In the CIA model, SH3BP2 deficiency
suppressed the incidence of arthritis and this was
associated with decreased anti-CII antibody production,
while antigen-specific T cell responses in lymph nodes
were not significantly different between Sh3bp2/ and
Sh3bp2/ mice.
Conclusion. SH3BP2 deficiency prevents loss of
bone via impaired osteoclastogenesis in the hTNF-Tg
mouse model and suppresses the induction of arthritis
via decreased autoantibody production in the CIA
model. Therefore, SH3BP2 could potentially be a ther-
apeutic target in rheumatoid arthritis.
Rheumatoid arthritis (RA) is a chronic inflam-
matory bone-destructive disorder with autoimmune fea-
tures. It is driven by diverse cellular and humoral
immune responses, resulting in bone destruction. Bone
loss in RA is caused by osteoclasts (1–3). Osteoclast
differentiation is controlled mainly by RANK and its
ligand, RANKL. RANKL is expressed on osteoblasts
and can be expressed by other cells, such as fibroblasts
and T cells, in inflammatory conditions (4–6). In RA,
tumor necrosis factor  (TNF) augments RANKL
expression in synovial fibroblasts and subsequently en-
hances osteoclastogenesis in inflamed joints (4–6). Ad-
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ditionally, TNF enhances osteoclastogenesis by acting
on osteoclast precursors directly or synergistically with
RANKL (7–10). Excessive osteoclast activity conse-
quently causes local and systemic bone loss (11,12).
Additionally, one of the characteristic features of RA is
the presence of autoantibodies, notably rheumatoid
factor and anti–citrullinated protein antibodies (3,13).
Autoantibody production by B cells is a major patho-
genic mechanism leading to chronic inflammation in
RA.
SH3 domain–binding protein 2 (SH3BP2) is an
adapter protein that is expressed primarily in immune
cells including T cells, B cells, and macrophages, as well
as osteoclasts. It interacts with various proteins, includ-
ing Syk (14), phospholipase C (14,15), and Src (16,17),
and regulates intracellular signaling pathways in the
immune and skeletal systems (18–21). It has previously
been reported (22,23) that gain-of-function mutations in
Sh3bp2 cause cherubism (OMIM no. #118400), a hu-
man craniofacial disorder characterized by excessive
jawbone destruction (24). The jaw lesions in cherubism
consist mainly of fibroblastoid cells with numerous
tartrate-resistant acid phosphatase (TRAP)–positive
multinucleated giant cells (24,25), suggesting that the
excessive bone resorption is caused by increased osteo-
clast formation.
A mouse model of cherubism has been generated
by knocking-in a P416R Sh3bp2 mutation (equivalent to
the most common P418R mutation in cherubism pa-
tients) (21). Analysis of the mouse model has revealed
that heterozygous (Sh3bp2P416R/) mice exhibit osteo-
penia due to increased RANKL-induced osteoclasto-
genesis (21). Unexpectedly, homozygous mutants
(Sh3bp2P416R/P416R mice) spontaneously develop severe
arthritis. In SH3BP2-deficient mice, B cell proliferation
and signaling in response to B cell antigen receptor
ligation have been shown to be impaired, although no
abnormalities in T cell function were observed (18,19).
Furthermore, SH3BP2 loss-of-function suppresses
RANKL-induced osteoclastogenesis (16,17,26). These
findings suggest a potential pathologic link between
SH3BP2 and arthritis, through the SH3BP2-induced
modulation of osteoclastogenesis and autoimmune reac-
tions. However, the exact mechanisms by which SH3BP2
regulates arthritis have not been clarified.
In this study, we hypothesized that SH3BP2 plays
a role in the pathogenesis of bone-destructive inflamma-
tory diseases such as RA, in which TNF and autoanti-
body production are critically involved (3). To test this
hypothesis, we used 2 different murine arthritis models,
a human TNF–transgenic (hTNF-Tg) mouse model
(27,28) and a collagen-induced arthritis (CIA) model
(29,30). We demonstrated that SH3BP2 deficiency pre-
vents bone loss via impaired osteoclastogenesis in the
hTNF-Tg model and suppresses the induction of arthri-
tis via decreased autoantibody production in the CIA
model.
MATERIALS AND METHODS
Mice. TNF-Tg mice (C57BL/6 background) were ob-
tained from Taconic (27) and crossed with Sh3bp2/ mice
(C57BL/6 background) (18). DBA/1J mice were purchased
from The Jackson Laboratory. Sh3bp2/ mice were back-
crossed for 10 generations onto a DBA/1 background and
used for CIA experiments. Mice were housed in a specific
pathogen–free facility. All experimental procedures were ap-
proved by the Institutional Animal Care and Use Committees.
Reagents. Recombinant murine macrophage colony-
stimulating factor (M-CSF), RANKL, and TNF were ob-
tained from PeproTech. Chick type II collagen (CII), Freund’s
complete adjuvant (CFA), and anti–mouse CII antibody assay
kits were purchased from Chondrex.
Evaluation of arthritis in hTNF-Tg mice. Arthritis
severity in Sh3bp2//hTNF-Tg and Sh3bp2//hTNF-Tg
mice was scored, under blinded conditions, once per week until
16 weeks of age, using the following criteria: 0  normal; 1 
mild erythema or swelling of the wrist or ankle, or erythema
and swelling of 1 digit; 2  moderate erythema and swelling of
the wrist or ankle, or 3 inflamed digits; 3  severe erythema
and swelling of the wrist or ankle; and 4  complete erythema
and swelling of the wrist and ankle, including all digits. Each
limb was graded separately, yielding a maximum possible total
score of 16. At 16 weeks of age, the mice were killed and serum
and hind limbs were collected. Serum concentrations of human
and mouse TNF were measured by enzyme-linked immu-
nosorbent assay (ELISA; R&D Systems). After fixation with
4% paraformaldehyde in phosphate buffered saline, hind limbs
were assessed radiologically and histologically.
Histologic and histomorphometric analysis. Hind
limbs were decalcified in 0.5M EDTA (pH 7.2) at 4°C for 4
weeks and embedded in paraffin. Sections (6 m) were stained
with hematoxylin and eosin and Safranin O. The severity of
inflammation and of cartilage damage was scored, under
blinded conditions, by 2 independent observers (TM and RG)
using the following criteria: for inflammation, 0  normal; 1 
mild diffuse inflammatory infiltrates; 2  moderate inflamma-
tory infiltrates; 3  marked inflammatory infiltrates; and 4 
severe inflammation with pannus formation; for cartilage
damage, 0  normal; 1  mild loss of Safranin O staining with
no obvious chondrocyte loss; 2  moderate loss of staining
with focal mild chondrocyte loss; 3  marked loss of staining
with multifocal marked chondrocyte loss; and 4  severe
diffuse loss of staining with multifocal severe chondrocyte
loss. TRAP staining with methyl green counterstaining was
performed to visualize TRAP cells. Histomorphometric
measurements were performed using OsteoMeasure software
(OsteoMetrics). TRAP multinucleated cells (MNCs) con-
taining 3 nuclei were defined as osteoclasts. Eroded surface/
bone surface (ES/BS) and osteoclast number/bone surface
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(N.Oc/BS) of talus were determined. The terminology used
and units reported were based on international guidelines (31).
Micro–computed tomographic (micro-CT) analysis.
Left hind limbs were scanned with a vivaCT 40 (Scanco
Medical). The threshold was set to 300 for hind paw bone, 260
for cortical bone of the tibia, and 220 for trabecular bone of the
tibia to distinguish mineralized tissue. Talar bone volume was
quantified to evaluate bone erosion (32). The regions of tibial
trabecular and cortical bone were selected as described previ-
ously (33). All micro-CT parameters were consistent with
international guidelines (34).
Osteoclast differentiation assay. Primary bone marrow
cell culture was performed as previously described (21). Mouse
bone marrow cells were isolated from long bones of 9-week-old
female Sh3bp2/ and Sh3bp2/ mice and cultured on petri
dishes for 2–4 hours. Nonadherent cells were reseeded on
48-well plates at 2.1  104 cells/well and incubated at 37°C/5%
CO2 for 2 days in -minimum essential medium/10% fetal
bovine serum containing M-CSF (25 ng/ml). Bone marrow–
derived M-CSF–dependent macrophages (BMMs) were stim-
ulated with RANKL and TNF in the presence of M-CSF
(25 ng/ml) for an additional 4 days. Culture media were
changed every other day. TRAP MNCs (3 nuclei) were
visualized by TRAP staining (Sigma-Aldrich) and counted at
40 magnification (n  4–6 wells/group).
Resorption assay. Dentin slices were sterilized in 70%
ethanol, washed with phosphate buffered saline, and placed on
the bottom of 96-well plates. Nonadherent bone marrow cells
were plated at 8.5  103 cells/well. After 2-day preculture with
M-CSF, BMMs were stimulated with RANKL and TNF in
the presence of M-CSF (25 ng/ml) for 14 days. After removal
of the cells with 1M NH4OH, resorption areas were visualized
with toluidine blue, followed by quantification with ImageJ
(National Institutes of Health).
Real-time quantitative polymerase chain reaction
(PCR). Total RNA was extracted using TRIzol (Invitrogen).
Complementary DNA was transcribed with High Capacity
cDNA Reverse Transcription Kits (Applied Biosystems).
Quantitative PCR was performed using Absolute Blue qPCR
Master Mix (Thermo Scientific) with a StepOne Plus system
(Applied Biosystems). Gene expression levels relative to Hprt
were calculated by the Ct method and were normalized to
baseline controls. Primers were as follows: Tnfa 5-CATCTT-
CTCAAAATTCGAGTGACA-3 (forward), 5-TGGGAGT-
AGACAAGGTACAACCC-3 (reverse); Acp5 5-CAGCAG-
CCCAAAATGCCT-3 (forward), 5-TTTTGAGCCAGGAC-
AGCTGA-3 (reverse); Ctsk 5-CGAAAAGAGCCTAGCG-
AACA-3 (forward), 5-TGGGTAGCAGCAGAAACTTG-3
(reverse); Oscar 5-TCTGCCCCCTATGTGCTATCA-3
(forward), 5-AGGAGCCAGAACCTTCGAAAC-3 (re-
verse); Hprt, 5-TCCTCCTCAGACCGCTTTT-3 (forward),
5-CCTGGTTCATCATCGCTAATC-3 (reverse). All quanti-
tative PCRs yielded products with single-peak dissociation
curves.
Western blotting. For nuclear and cytoplasmic frac-
tionation, BMMs were lysed on ice in cytoplasmic lysis buffer
with protease inhibitors (Sigma-Aldrich), and nuclei were lysed
in nuclear lysis buffer as described previously (33). Nuclear
protein (1 g/lane) and cytoplasmic protein (4 g/lane) were
resolved by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis and transferred to nitrocellulose membranes. After
blocking with 5% skim milk, membranes were incubated with
primary antibodies and then with horseradish peroxidase–
conjugated secondary antibodies (Cell Signaling Technology).
Bands were detected using SuperSignal West chemilumines-
cent substrates (Thermo Scientific) and visualized with LAS-
4000 (GE Healthcare).
Induction of CIA. Nine-week-old male Sh3bp2/ and
Sh3bp2/ mice (DBA/1 background) were injected intra-
dermally with 100 g chick CII with CFA at the base of the tail
on day 0 (35,36). On day 21, a booster injection of 100 g chick
CII in Freund’s incomplete adjuvant was administered. Arthri-
tis severity was assessed, under blinded conditions, twice per
week until day 70, using the same criteria as were applied for
the hTNF-Tg mice.
ELISA for anti–mouse CII antibody. Serum levels of
anti–mouse CII antibody (total IgG, IgG1, IgG2a, and IgG2b)
were measured according to the protocol recommended by
the manufacturer of the ELISA Kit (Chondrex). Diluted
serum samples were added to mouse CII–coated 96-well plates
and incubated at 4°C overnight. Bound IgG was detected by
incubation with horseradish peroxidase–conjugated anti-
mouse IgG followed by o-phenylenediamine substrate.
Cell proliferation and cytokine production in draining
lymph node cell culture. Nine-week-old male Sh3bp2/ and
Sh3bp2/mice were immunized with 100 g chick CII in
CFA. Ten days after immunization, inguinal lymph nodes were
isolated. Lymph node cells were cultured at 4  105 cells/well
in 96-well U-bottomed plates in RPMI1640 with 10% heat-
inactivated fetal bovine serum, 50 M 2-mercaptoethanol, and
1% L-glutamine at 37°C/5% CO2 (37). The cells were stimu-
lated for 72 hours with 50 g/ml denatured chick CII. Cell
proliferation was determined using CellTiter 96 Proliferation
Assay (MTS) reagent according to the instructions of the
manufacturer (Promega). Levels of interferon- (IFN) and
interleukin-17 (IL-17) in media were determined by ELISA
(R&D Systems).
Statistical analysis. Mean  SEM values were deter-
mined, and statistical analysis was performed by Student’s
unpaired 2-tailed t-test to compare 2 groups and by one-way
analysis of variance with Tukey-Kramer post hoc test to
compare 3 or more groups. The significance of differences in
arthritis incidence rates was assessed by Fisher’s exact test.
GraphPad Prism 5 was used for all statistical analyses. P values
less than 0.05 were considered significant.
RESULTS
Suppressed bone erosion in Sh3bp2-deficient
hTNF-Tg mice. To investigate the role of SH3BP2 in the
pathogenesis of arthritis, we crossed SH3BP2-deficient
mice with hTNF-Tg mice, which spontaneously produce
TNF and develop TNF-dependent arthritis (27,28).
We found that both Sh3bp2//hTNF-Tg and Sh3bp2//
hTNF-Tg mice developed severe arthritis and that the
severity of arthritis was comparable between them (Figure
1A). Serum levels of human and murine TNF were also
similar in Sh3bp2//hTNF-Tg and Sh3bp2//hTNF-Tg
mice (Figure 1B). These data suggest that SH3BP2 defi-
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ciency does not significantly affect the severity of joint
inflammation and systemic TNF production.
Next, we examined the severity of inflamma-
tory cell infiltration, cartilage damage, and bone erosion
in tibiotalar joints. Histologic examination showed
that both Sh3bp2//hTNF-Tg mice and Sh3bp2//
hTNF-Tg mice developed severe inflammation, but
Sh3bp2//hTNF-Tg mice exhibited less bone erosion
(Figure 1C). Quantitative histologic analysis revealed
that the inflammation score and the cartilage damage
score were comparable between Sh3bp2//hTNF-Tg
and Sh3bp2//hTNF-Tg mice (Figure 1D). Histomor-
phometric analysis, in contrast, showed that ES/BS and
N.Oc/BS were lower in Sh3bp2//hTNF-Tg mice than
Figure 1. Decreased osteoclast formation and bone erosion in SH3BP2-deficient human tumor necrosis factor –transgenic (hTNF-Tg) mice.
Sh3bp2/ (/) and Sh3bp2/ (/) mice were crossed with hTNF-Tg mice. Joint inflammation was monitored through age 16 weeks, at which
time the mice were killed and serum and hind limbs collected for analysis. A, Clinically assessed joint inflammation scores in male Sh3bp2/ and
Sh3bp2/ mice (n  9 and n  7, respectively) and Sh3bp2//hTNF-Tg and Sh3bp2//hTNF-Tg mice (n  7 and n  9, respectively). B, Serum
concentrations of human and mouse TNF in the 4 groups. C, Representative results of staining of ankle joint tissue from mice in the 4 groups. Ankle
joint sections were stained with hematoxylin and eosin (H&E), Safranin O, and tartrate-resistant acid phosphatase (TRAP). Original magnification
 40. D, Histologic scores of inflammation and cartilage damage and results of talar bone histomorphometric analysis (eroded surface/bone surface
[ES/BS] and osteoclast number/bone surface [N.Oc/BS]) of mice in the 4 groups. Bone erosion on the surface of the talus was traced, and attached
osteoclasts were counted. Values are the mean  SEM.   P 	 0.05. NS  not significant; ND  not detectable.
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in Sh3bp2//hTNF-Tg mice (Figure 1D). These find-
ings indicate that SH3BP2 deficiency suppresses osteo-
clast formation and bone erosion in inflamed joints
without significantly affecting the severity of inflamma-
tion.
Decreased focal and systemic bone loss in
SH3BP2-deficient hTNF-Tg mice. Arthritic conditions
cause focal bone loss in inflamed joints, as well as
systemic bone loss (11,12). We assessed the bone prop-
erties of the talus and the tibia as parameters of focal
and systemic bone loss, respectively. Micro-CT analysis
revealed bone erosion on the talus of both Sh3bp2//
hTNF-Tg and Sh3bp2//hTNF-Tg mice, but the ero-
sion was milder in the Sh3bp2//hTNF-Tg mice (Fig-
ure 2A). To quantify the focal bone loss, the bone
volume (BV) of the talus and the percent change in BV
of the talus relative to that in noninflamed tali from
control mice were determined as previously described
(32). The average BV of the talus was greater in
Sh3bp2//hTNF-Tg mice than in Sh3bp2//hTNF-Tg
mice, and the percent change in BV of the talus was less
in Sh3bp2//hTNF-Tg mice (Figure 2B). To examine
whether SH3BP2 deficiency suppresses systemic bone
loss, properties of trabecular and cortical bone of the
tibia were determined. We found that bone volume/total
volume was greater in Sh3bp2//hTNF-Tg mice than in
Sh3bp2//hTNF-Tg mice, and the rate of trabecular
bone loss was smaller in Sh3bp2//hTNF-Tg mice than
in Sh3bp2//hTNF-Tg mice (Figure 2C). The results
were similar when cortical thickness of the tibia was
measured (Figure 2D). Taken together, these data show
that loss-of-function of SH3BP2 prevents focal and
systemic bone loss in the hTNF-Tg arthritis model.
TNF messenger RNA (mRNA) expression in
primary BMMs. It has previously been reported that
SH3BP2 plays a role in TNF production by macro-
phages, as demonstrated by the observation that the
P416R Sh3bp2 gain-of-function mutation in macro-
phages resulted in greater TNF production in response
to M-CSF compared to that observed in Sh3bp2/
mouse macrophages (21). To examine whether SH3BP2
deficiency suppresses TNF expression in macrophages,
Figure 2. Reduction of focal and systemic bone loss in SH3BP2-deficient human tumor necrosis factor –transgenic (hTNF-Tg) mice. Male
Sh3bp2/ (/) and Sh3bp2/ (/) mice (n  9 and n  7, respectively), and Sh3bp2//hTNF-Tg and Sh3bp2//hTNF-Tg mice (n  7 and
n  9, respectively) were killed at age 16 weeks, and left hind limbs were collected. The hind paws and tibiae were analyzed by micro–computed
tomography (micro-CT). A, Representative micro-CT images of hind paws, talar bones, and trabecular and cortical bones of the tibiae. Bars 1 mm
(hind paw) and 400 m (talus and tibia). B, Bone volume (BV) of the talus and percent change in BV relative to control Sh3bp2/ and Sh3bp2/
mice. C, Bone volume/total volume (BV/TV) in trabecular bone of proximal tibia and percent change in trabecular BV/TV relative to control
Sh3bp2/ and Sh3bp2/mice. D, Cortical thickness (Ct.Th) of the midshaft of the tibia and percent change in Ct.Th relative to control Sh3bp2/
and Sh3bp2/ mice. Values are the mean  SEM.   P 	 0.05 versus Sh3bp2//hTNF-Tg mice.
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we measured TNF mRNA expression levels in
Sh3bp2/ and Sh3bp2/ mouse BMMs in response to
M-CSF and TNF. Stimulation with M-CSF alone did
not increase the expression of mRNA for TNF during
the culture period (Figure 3A). TNF and M-CSF
together increased TNF mRNA expression (4-fold
increase at 24 hours after treatment), but expression
levels were comparable between Sh3bp2/ and
Sh3bp2/ mouse BMMs (Figure 3A). These results
suggest that SH3BP2 deficiency does not significantly
alter TNF expression in BMMs, consistent with the
absence of a difference in serum TNF levels between
Sh3bp2//hTNF-Tg and Sh3bp2//hTNF-Tg mice
(Figure 1B).
Impaired osteoclastogenesis in SH3BP2-deficient
primary BMMs. Decreased osteoclast formation and
bone erosion in the inflamed joints of Sh3bp2/ mice
led us to investigate the role of SH3BP2 in osteoclasto-
genesis. Since RANKL and TNF are involved in the
mechanisms of inflammatory bone resorption (4–6), we
focused on RANKL- and TNF-induced osteoclasto-
genesis. Sh3bp2/ and Sh3bp2/ mouse BMMs were
stimulated with RANKL and/or TNF in the presence
of M-CSF. We found that cell proliferation was compa-
Figure 3. Impaired osteoclast differentiation and bone-resorbing function in Sh3bp2/ (/) bone marrow–derived macrophages (BMMs).
Primary bone marrow cells were isolated and cultured as described in Materials and Methods. A, Expression of mRNA for tumor necrosis
factor  (TNF). BMMs were stimulated with TNF (100 ng/ml) in the presence of macrophage colony-stimulating factor (M-CSF; 25 ng/ml).
TNF mRNA expression levels relative to Hprt were calculated and normalized to the expression level in Sh3bp2/ (/) BMMs at time 0.
B, Representative images showing tartrate-resistant acid phosphatase (TRAP) staining under the different experimental conditions, and num-
ber of TRAP multinucleated cells (MNCs). BMMs were stimulated for 4 days with RANKL alone (50 ng/ml), the combination of RANKL
(50 ng/ml) and TNF (100 ng/ml), or TNF alone (100 ng/ml) in the presence of M-CSF (25 ng/ml). Original magnification  40. C, Representa-
tive images showing bone resorption areas on dentin (arrows indicate resorption pits), and quantification of the percentage of resorption area
relative to total surface area. BMMs were stimulated for 14 days with RANKL (50 ng/ml) and/or TNF (100 ng/ml) in the presence of M-CSF (25
ng/ml). After removal of the cells, resorption areas were visualized with toluidine blue. Values are the mean  SEM.   P 	 0.05. Original
magnification  40 in B;  50 in C. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/
art.38975/abstract.
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rable between Sh3bp2/ and Sh3bp2/ mouse BMMs
after the stimulation (data not shown). RANKL and
TNF, alone or in combination, induced TRAPMNC
formation in both Sh3bp2/ and Sh3bp2/ BMMs
(Figure 3B). Sh3bp2/ BMMs formed fewer TRAP
MNCs in response to TNF, while the numbers of
TRAP MNCs were comparable when the BMMs
were treated with RANKL or the combination of
RANKL and TNF (Figure 3B). Consistent with find-
ings described in a previous report (16), the size of the
TRAP MNCs from Sh3bp2/ mouse BMMs was
smaller than that from Sh3bp2/mouse BMMs (results
not shown).
Next, we investigated the bone-resorbing func-
tion of BMMs after stimulation with RANKL and
TNF. Although TNF alone did not induce detectable
resorption pits in Sh3bp2/ mouse BMM cultures,
synergistically with RANKL it enhanced resorption in
Sh3bp2/ mouse osteoclasts (Figure 3C). In contrast,
the synergistic induction of resorption pits was much
lower in Sh3bp2/ mouse BMMs.
Taken together, the data demonstrate that SH3BP2
deficiency reduces TRAP MNC formation by TNF
and inhibits osteoclastic resorbing function in response
to RANKL, particularly in the presence of TNF.
These findings suggest that loss of SH3BP2 function
ameliorates focal and systemic bone loss in the hTNF-Tg
arthritis model by reducing the formation of functional
osteoclasts in response to RANKL and TNF.
Decreased NF-ATc1 nuclear localization in
TNF-stimulated Sh3bp2/ mouse BMMs. We next
investigated the mechanism by which lack of SH3BP2
impairs RANKL- and TNF-induced osteoclastogen-
esis. Since previous studies have shown that SH3BP2
regulates RANKL-induced osteoclastogenesis via acti-
vation of NF-ATc1 (17,21,26,38), which is an essential
transcription factor for osteoclastogenesis (38,39), we
focused on levels of NF-ATc1 in BMMs. We found
that nuclear expression of NF-ATc1 was decreased in
Sh3bp2/ mouse BMMs compared to Sh3bp2/
mouse BMMs at 48–72 hours after stimulation with
RANKL, TNF, or the combination of both; this de-
crease was particularly marked upon stimulation with
TNF alone (Figure 4A). Nuclear expression patterns of
Figure 4. Reduced NF-ATc1 nuclear localization in Sh3bp2/ mouse BMMs treated with TNF. BMMs were stimulated with RANKL alone
(50 ng/ml), the combination of RANKL (50 ng/ml) and TNF (100 ng/ml), or TNF alone (100 ng/ml) in the presence of M-CSF (25 ng/ml). A,
Western blot analysis of NF-ATc1. Nuclear and cytoplasmic protein samples were isolated at the indicated time points after stimulation. Nuclear
matrix protein p84 and Hsp90 were used as loading controls. B, Quantitative polymerase chain reaction analysis of the expression of Acp5, Ctsk, and
Oscar. Expression levels of mRNA for the genes relative to Hprt mRNA were calculated and normalized to the average expression levels in
Sh3bp2/ mouse BMMs at time 0. Values are the mean  SEM.   P 	 0.05. NS  not significant (see Figure 3 for other definitions).
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other transcription factors, such as NF-B, c-Fos, c-Jun,
and IFN regulatory factor 8, which also regulate osteo-
clastogenesis (40,41), in response to TNF did not differ
between Sh3bp2/ and Sh3bp2/ mouse BMMs (re-
sults not shown). These findings suggest that decreased
NF-ATc1 nuclear localization in Sh3bp2/ mouse
BMMs is, at least in part, responsible for the diminished
formation of active osteoclasts in vivo and in vitro.
Since osteoclast-associated genes are primarily
regulated by NF-ATc1 (38), we next examined the
expression of Acp5, Ctsk, and Oscar in Sh3bp2/ and
Sh3bp2/ mouse BMMs stimulated with RANKL,
TNF, or the combination of both. We found that
expression levels of the genes in Sh3bp2/ mouse
BMMs stimulated with RANKL or TNF were reduced
compared to expression levels in Sh3bp2/ BMMs
(Figure 4B). These results were similar to the previously
reported finding that reduced function of SH3BP2 sup-
presses the expression of osteoclast-associated genes in
RANKL-induced osteoclastogenesis (17,26) and support
the observation that NF-ATc1 nuclear localization was
decreased in TRAP MNCs from Sh3bp2/ mice.
However, expression levels of the osteoclast-associated
genes were not significantly reduced in response to
simultaneous stimulation with RANKL and TNF (Fig-
ure 4B), the condition under which TRAPMNCs from
Sh3bp2/ mice exhibited a significantly decreased re-
sorption area (Figure 3C). This suggests that SH3BP2
could regulate bone resorption independently of
NF-ATc1 activation, at least in response to combined
treatment with RANKL and TNF.
Reduced incidence and severity of arthritis in
CII-immunized Sh3bp2/ mice. SH3BP2 is expressed
in various immune cells including T and B cells (18,19),
and we investigated whether SH3BP2 regulates the
development of arthritis in CIA, a model in which T and
B cells have essential pathogenetic roles. After immuni-
zation of Sh3bp2/ and Sh3bp2/ DBA/1 mice with
CII, Sh3bp2/ mice developed arthritis at a rate of
100% (10 of 10 mice), while the induction of arthritis in
Sh3bp2/ mice was significantly suppressed (15% [2 of
13 mice]) (Figure 5A). Additionally, the severity of
arthritis in Sh3bp2/ mice was much lower than that in
Sh3bp2/ mice (Figure 5B). These findings indicate
that SH3BP2 deficiency suppresses the development of
arthritis in the CIA model.
Decreased inflammation and cartilage damage in
the joints of Sh3bp2/ mice. To determine the effects
of SH3BP2 deficiency on inflammation, cartilage dam-
age, and bone erosion in the CIA model, ankle joints of
CII-immunized Sh3bp2/ and Sh3bp2/ mice (n  10
and n  13, respectively) as well as nonimmunized
Sh3bp2/ and Sh3bp2/ controls (n  7 and n  7,
respectively) were assessed histologically. We found that
CII-immunized Sh3bp2/ mice developed severe in-
flammation, cartilage damage, and bone erosion with
osteoclast formation, while inflammation, cartilage dam-
age, and bone erosion in CII-immunized Sh3bp2/
mice were much milder, with decreased osteoclast for-
Figure 5. Decreased incidence and severity of arthritis in Sh3bp2/
mice in the collagen-induced arthritis model. Nine-week-old male
Sh3bp2/ and Sh3bp2/mice (n 10 and n 13, respectively) were
immunized with chick type II collagen (CII) in Freund’s complete
adjuvant on day 0, followed by a booster injection on day 21. Swelling
of the paws was evaluated through day 70, at which time the mice were
killed and hind limbs collected for analysis, with age-matched nonim-
munized Sh3bp2/ and Sh3bp2/ mice (n  7 and n  7, respec-
tively) used as controls. A, Incidence of arthritis. B, Mean  SEM
arthritis scores. C, Representative results of staining of ankle joint
tissue from mice in the 4 groups. Ankle joint sections were stained with
H&E, Safranin O, and TRAP. Original magnification  40. D,
Mean  SEM histologic scores of inflammation and cartilage damage
and results of talar bone histomorphometric analysis (eroded surface/
bone surface and osteoclast number/bone surface) of mice in the 4
groups. Bone erosion on the surface of the talus was traced, and
attached osteoclasts were counted.   P 	 0.05 versus Sh3bp2/
mice. See Figure 1 for other definitions. Color figure can be viewed in
the online issue, which is available at http://onlinelibrary.wiley.com/
doi/10.1002/art.38975/abstract.
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mation compared to that observed in CII-immunized
Sh3bp2/ mice (Figure 5C). The findings were con-
firmed by quantitative analysis of inflammation and
cartilage damage and by histomorphometric analysis
(Figure 5D). These data suggest that SH3BP2 deficiency
reduces the severity of inflammation, cartilage damage,
and bone erosion, reflecting decreased joint inflamma-
tion and osteoclast formation, in Sh3bp2/ mice.
Suppression of serum anti–mouse CII antibody
levels in Sh3bp2/ mice. To investigate the mecha-
nisms underlying the suppressed induction of arthritis in
Sh3bp2/ mice in the CIA model, we measured levels
of serum autoantibodies, which are important in the
induction of CIA (29,30). As shown in Figure 6A, mouse
CII total IgG levels on day 70 were increased in CII-
immunized Sh3bp2/ mice, while SH3BP2 deficiency
dramatically suppressed the serum levels of the anti-
body. The IgG1, IgG2a, and IgG2b subclasses of anti-
CII antibody were all decreased in CII-immunized
Sh3bp2/ mice as well. These results indicate that
suppressed induction of arthritis in Sh3bp2/ mice is
associated with reduced production of anti–mouse CII
antibodies.
No significant abnormality in proliferation or
IFN and IL-17 production in Sh3bp2/ draining
lymph node cell cultures. T cells also play critical roles in
the initiation of arthritis in the CIA model (29,30). To
evaluate whether impaired T cell function is involved in
the decreased development of CIA in Sh3bp2/ mice,
inguinal lymph nodes were isolated 10 days after immu-
nization with CII, and cell proliferation and levels of
IFN and IL-17 production in response to chick CII
were determined. We found that cell proliferation and
cytokine levels in the media were comparable between
the CII-immunized Sh3bp2/ and Sh3bp2/ mice
(Figures 6B and C). These results suggest that SH3BP2
Figure 6. Impaired anti–mouse type II collagen (CII) antibody production in Sh3bp2/ mice. A, Serum samples from male CII-immunized
Sh3bp2/ and Sh3bp2/ mice (n  10 and n  13, respectively) were collected on day 70, with age-matched nonimmunized Sh3bp2/ and
Sh3bp2/ mice (n  7 and n  7, respectively) used as controls. Total IgG, IgG1, IgG2a, and IgG2b anti–mouse CII were measured by
enzyme-linked immunosorbent assay (ELISA). B and C, Inguinal lymph nodes from CII-immunized mice were isolated 10 days after immunization,
with age-matched nonimmunized mice used as controls. Lymph node cells (4 105 cells/well) were stimulated with chick CII (50 g/ml) for 72 hours.
Proliferation of the cells was determined by colorimetric assay using MTS reagent (B), and levels of interferon- (IFN) and interleukin-17 (IL-17)
in culture supernatant were measured by ELISA (lower limit of detection 10 pg/ml) (C). Values are the mean  SEM.   P 	 0.05. PBS 
phosphate buffered saline (see Figure 1 for other definitions).
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deficiency does not significantly alter the pathogenic T
cell responses in CIA, in contrast to impaired production
of the associated autoantibodies.
DISCUSSION
Previous studies of SH3BP2-deficient mice have
shown that, under physiologic conditions, SH3BP2 has
an important role in RANKL-induced osteoclastic bone
resorption (16). In the present study we demonstrated,
using 2 different arthritis models, that the lack of
SH3BP2 suppresses inflammatory bone destruction in
hTNF-Tg mice and mice with CIA.
There is accumulating evidence suggesting that
RANKL and TNF play important roles in inflamma-
tory bone-destructive diseases such as RA (4–6). We
hypothesized that SH3BP2 contributes to RANKL- and
TNF-induced osteoclastogenesis in pathologic inflam-
matory conditions and obtained several pieces of evi-
dence to support this hypothesis. First, loss-of-function
of SH3BP2 ameliorated inflammatory bone destruction
in hTNF-Tg mice, in conjunction with reduced numbers
of TRAP MNCs. Second, RANKL- and TNF-
induced osteoclastogenesis was impaired in SH3BP2-
deficient mouse BMMs. Third, NF-ATc1 induction and
expression of osteoclast-associated genes (Acp5, Ctsk,
and Oscar) in Sh3bp2/ mouse BMMs were reduced in
response to TNF. In addition to its direct effect on
TRAP MNC formation, TNF potentiates functional
osteoclast formation synergistically with RANKL
(7,9,10). Based on these results, we conclude that
SH3BP2 plays an important role in both RANKL- and
TNF-induced osteoclastogenesis and regulates bone
destruction in pathologic inflammatory conditions by
modulating responsiveness to RANKL and TNF.
Consistent with the previous report (16), we
showed that SH3BP2 deficiency suppresses RANKL-
induced osteoclastic bone resorption, but not RANKL-
induced TRAP MNC formation (Figures 3B and C).
Interestingly, our study also revealed that SH3BP2 de-
ficiency suppresses the formation of TRAP MNCs in
response to TNF (Figure 3B), suggesting that SH3BP2
regulates osteoclastogenesis by different mechanisms
under different conditions, i.e., RANKL stimulation and
TNF stimulation. In fact, the involvement of NF-ATc1
differs between these settings. Levaot et al reported that
SH3BP2 deficiency does not alter levels of NF-ATc1
nuclear localization in RANKL-stimulated BMMs (16),
while we found decreased NF-ATc1 nuclear localization
in TNF-stimulated Sh3bp2/ mouse BMMs. These
findings suggest that SH3BP2 modulates multiple path-
ways in osteoclast precursors depending on the type of
stimulation, presumably by interacting with different
signaling molecules. Indeed, several differences in reg-
ulatory mechanisms between RANKL- and TNF-
induced osteoclastogenesis have been reported (41,42).
We showed that SH3BP2 deficiency dramatically sup-
presses resorption area in response to combined treat-
ment with RANKL and TNF (Figure 3C), but exhibits
a relatively small suppressive effect on nuclear NF-ATc1
localization in response to this combined treatment
(Figure 4A). These findings raise the possibility that
SH3BP2 could regulate bone resorption independently
of NF-ATc1–mediated pathways. Further study would
be needed to test this hypothesis.
Blocking of SH3BP2 function may be of benefit
in the treatment of autoimmune inflammatory diseases.
In the present study, we found that SH3BP2 deficiency
suppresses the induction of CIA associated with de-
creased autoantibody production, while T cell responses
against CII are not significantly affected. These results
are supported by the findings of previous studies dem-
onstrating essential roles of SH3BP2 in B cell activation.
SH3BP2 has been shown to be required for optimal B
cell responses without noticeably affecting T cell func-
tion in Sh3bp2/ mice (18,19). In B cells, SH3BP2
regulates cell proliferation, cell cycle progression, and
intracellular signaling pathways downstream of B cell
antigen receptor. Intriguingly, SH3BP2 activates NF-AT
in B cells through mechanisms similar to those it exerts
in osteoclasts (43,44). Considering the fact that SH3BP2
deficiency reduces pathogenic autoantibody production
in the CIA model, therapeutic strategies designed to
suppress its function may be effective in antibody-
induced diseases such as systemic lupus erythematosus
or refractory immune thrombocytopenia.
Besides monocyte-lineage cells and B cells,
SH3BP2 plays functional roles in various immune cells,
including natural killer cells, neutrophils, and mast cells
(15,45,46). Given the fact that these cells are also
involved in the pathogenesis of RA (3,47–49), SH3BP2
might contribute to the development of the disease
through its effects in the immune cells. Additionally, we
cannot exclude the possibility that SH3BP2 regulates
osteoclastogenesis indirectly via osteoblasts and synovial
fibroblasts in vivo (50). To achieve better understanding
of SH3BP2 function, in vitro analysis with specific cell
types isolated from SH3BP2-deficient mice and analysis
of SH3BP2–conditional-knockout mice or bone marrow
chimera models comparing SH3BP2-deficient and wild-
type mice would be beneficial.
In conclusion, we have demonstrated that lack of
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SH3BP2 decreases inflammatory bone loss via impaired
osteoclastogenesis in the hTNF-Tg arthritis model and
that SH3BP2 deficiency suppresses induction of arthritis
via decreased autoantibody production in the CIA
model. These findings suggest that SH3BP2 could be a
potential therapeutic target in RA. Although a direct
association between SH3BP2 and RA has not yet been
identified, genetic variations that affect the expression
or functional level of SH3BP2 may regulate susceptibil-
ity to and severity of RA, especially through the mech-
anisms that control autoantibody production by B cells
and bone loss by osteoclasts. Further analysis is needed
to determine whether activation of SH3BP2-mediated
pathways in B cells and osteoclast precursors is involved
in the autoimmune and bone-destructive features of
human diseases.
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